<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04419337</url>
  </required_header>
  <id_info>
    <org_study_id>MOST 108-2314-B-182-017-</org_study_id>
    <nct_id>NCT04419337</nct_id>
  </id_info>
  <brief_title>Antidiabetic Triple Therapy Effects on Surrogate Tests After Stroke</brief_title>
  <acronym>ATTESTS</acronym>
  <official_title>Antidiabetic Triple Therapy Effects on Surrogate Tests After Stroke: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiayi Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Diabetes mellitus is a major risk factor of ischemic stroke. It is unsettled
      issue for which antidiabetic drugs is the best strategy for stroke patients with diabetes
      mellitus. Therefore it is important to figure out the most efficient way to prevent
      cardiovascular event in stroke patients. High-sensitivity C-reactive protein (hsCRP) is a
      marker of inflammation and its level can independently predict risk of cardiovascular disease
      and can be used as a surrogate for future cardiovascular event.

      Objective: To clarify whether triple therapy with combination with metformin, pioglitazone,
      and an SGLT2 inhibitor (empagliflozin or dapagliflozin or canagliflozin) for 6 months can
      reduce hsCRP in stroke patients with diabetes mellitus.

      Methods: This study will be conducted in 8 hospitals in Taiwan, enrolling 200 patients.
      Inclusion criteria were ischemic stroke within 6 months, having diabetes with Hb1c &gt; 7%, eGFR
      &gt; 45, no history of heart failure or amputation, and willing to sign informed consent.
      Patients will be randomly assigned to active treatment and conventional groups. In active
      arm, physicians will prescribe metformin, pioglitazone, and an SGLT2 inhibitor. In control
      arm, physicians will prescribe antidiabetic drug based on their personal experience.
      Treatment duration will be 6 months. The primary endpoint is hsCRP change from baseline in
      active vs control arm. The secondary endpoints are insulin resistance, BNP, albuminuria
      change from baseline in active vs control arm.

      Expectation: IF combination therapy with metformin, pioglitazone, and an SGLT2 inhibitor is
      able to reduce inflammation and other biomarkers, such approach can be considered as priority
      therapy for ischemic stroke patients with diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hsCRP (high-sensitivity C-reactive protein)</measure>
    <time_frame>6 months</time_frame>
    <description>hsCRP change from baseline (i.e. 6-month hsCRP-baseline hsCRP) in active vs control groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>6 months</time_frame>
    <description>to evaluate insulin resistance in active vs control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BNP</measure>
    <time_frame>6 months</time_frame>
    <description>use BNP as an index of heart failure between active vs control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UACR</measure>
    <time_frame>6 months</time_frame>
    <description>to evaluate microalbuminuria in active vs control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hba1C</measure>
    <time_frame>6 months</time_frame>
    <description>to evaluate glucose control in active vs control arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Active arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metformin+pioglitazone+an SGLT2 inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin with or without combination with following oral antidiabetic drugs: DPP4 inhibitor, sulfonylurea, and acarbose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin plus Pioglitazone plus an SGLT2 inhibitor</intervention_name>
    <description>Patients assigned to active group will stop their prior oral antidiabetic drugs and receive combination of metformin, pioglitazone, and an SGLT2 inhibitor (empagliflozin or dapagliflozin or canagliflozin) and dose will be adjusted by their physicians.</description>
    <arm_group_label>Active arm</arm_group_label>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ischemic stroke within 6 months of randomization

          2. Type 2 diabetes mellitus and Hba1C &gt; 7.0% and under metformin currently or previously
             with or without other antidiabetic drugs

          3. Estimated glomerular filtration rate (eGFR) &gt; 45 mL/min/1.73 m2

          4. Age â‰¥ 20 y at study entry

          5. Ability and willingness to provide informed consent

        Exclusion Criteria:

          1. History of congestive heart failure (NYHA class 1-4)

          2. History of bladder cancer

          3. History of repeated (&gt; 2 episodes) urinary tract infection or genital tract infection

          4. History of amputation

          5. Irreversible medical conditions with predicted survival &lt; 1 years

          6. ALT &gt; 100 mg/dl

          7. Currently use insulin injection to control blood glucose

          8. Currently use Glucagon-like peptide-1 receptor agonist to control blood glucose

          9. Currently use pioglitazone or SGLT-2 inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meng Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital, Chiayi Branch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meng Lee, MD</last_name>
    <phone>8863621000</phone>
    <phone_ext>2806</phone_ext>
    <email>menlee5126@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Chiayi Branch</name>
      <address>
        <city>Chiayi City</city>
        <zip>613</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meng Lee, MD</last_name>
      <phone>88653621000</phone>
      <phone_ext>2806</phone_ext>
      <email>menglee5126@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>sodium-glucose transport protein 2 inhibitor</keyword>
  <keyword>pioglitazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

